JNJ News Alert Johnson & Johnson (JNJ) 103.28 01/06/2015 17:

New Post Public Reply Private Reply Replies (0) Message Board

Jan 6, 2015 at 6:57 PM

Johnson & Johnson (JNJ) 103.28 $JNJ

Final Glance: Pharmaceuticals companies
AP - 53 mins ago
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
JNJ: 103.28 (-0.51), BAX: 71.11 (-0.38), PFE: 31.42 (+0.26), BMY: 58.48 (-0.10)

Final Glance: Medical Devices companies
AP - 53 mins ago
NEW YORK (AP) — Shares of some top medical devices companies were down at the close of trading:
ZMH: 115.80 (-0.99), JNJ: 103.28 (-0.51), MDT: 71.22 (-0.36), BAX: 71.11 (-0.38)

Pharmacyclics Reports Encouraging Data on Cancer Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 1 hr 12 mins ago
Pharmacyclics, Inc. (PCYC) announced encouraging data on its oncology drug, Imbruvica.
AGN: 209.37 (-2.06), JNJ: 103.28 (-0.51), PCYC: 119.85 (-0.12), ABBV: 64.33 (-0.32)

AOL and Gilead Sciences are big market movers
AP - 27 mins ago
NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq Stock Market:
F: 14.62 (-0.14), K.TO: 3.95 (+0.47), CS: 23.81 (-0.43), BBEP: 6.90 (+0.08), SDRL: 10.48 (-0.33), NBG: 1.58 (-0.08), CYBX: 54.36 (-3.43), JNJ: 103.28 (-0.51), ISIS: 65.44 (-2.73), KGC: 3.33 (+0.38), AOL: 46.25 (+1.51), CVEO: 3.11 (-0.32), EBIX: 18.60 (+2.32), THLD: 3.55 (-0.13), CEMP: 23.15 (-1.40), VZ: 47.04 (+0.47), XOOM: 16.82 (-0.07)

Isis Pharmaceuticals Up on Collaboration with J&J - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 2 hrs 37 mins ago
Isis Pharmaceuticals (ISIS) inked a global collaboration with Johnson & Johnson's (JNJ) Janssen Biotech, Inc for the discovery and development of antisense drugs for treating autoimmune disorders of the gastrointestinal tract.
BIIB: 334.65 (-2.09), JNJ: 103.28 (-0.51), ISIS: 65.44 (-2.73), AZN: 68.16 (-1.70)

Johnson & Johnson begins Ebola vaccine testing in humans
AP - Tue Jan 06, 2:27PM CST
NEW BRUNSWICK, N.J. (AP) — Johnson & Johnson has begun testing an Ebola vaccine in humans intended to counter a strain of the virus similar to the one that has wreaked havoc in West Africa.
JNJ: 103.28 (-0.51)

Selling Guidelines For Self Directed Investors
Chowder - at Seeking Alpha - Tue Jan 06, 2:13PM CST

HYH: 45.65 (+0.88), ABT: 44.40 (-0.51), FTR: 6.44 (-0.06), MDLZ: 35.99 (-0.25), DUK: 84.20 (+1.36), NUE: 46.46 (-0.68), ED: 66.08 (+0.37), KMB: 113.78 (-1.11), KRFT: 61.86 (+0.01), SDRL: 10.48 (-0.33), HCBK: 9.56 (-0.20), WM: 51.27 (+0.04), DRI: 58.19 (+0.20), JNJ: 103.28 (-0.51), CDK: 39.71 (-0.11), ADP: 82.54 (-0.69), LNCO: 11.31 (+0.09), TOO: 23.95 (-0.07), BP: 35.83 (-0.27), ABBV: 64.33 (-0.32), PG: 89.60 (-0.41), GIS: 52.02 (-0.13), CTL: 38.27 (-0.48)

Midday Glance: Pharmaceuticals companies
AP - Tue Jan 06, 12:17PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
JNJ: 103.28 (-0.51), BAX: 71.11 (-0.38), PFE: 31.42 (+0.26), BMY: 58.48 (-0.10)

Midday Glance: Medical Devices companies
AP - Tue Jan 06, 12:17PM CST
NEW YORK (AP) — Shares of some top medical devices companies are down at 1 p.m.:
ZMH: 115.80 (-0.99), JNJ: 103.28 (-0.51), MDT: 71.22 (-0.36), BAX: 71.11 (-0.38)

Why Biogen Idec Inc. Stock Catapulted 10% Higher in December
Sean Williams, The Motley Fool - Motley Fool - Tue Jan 06, 10:31AM CST
What: Shares of Biogen Idec , a biotech juggernaut primarily focused on treating multiple sclerosis and autoimmune disorders, scorched higher by 10% in December, based on data from S&P Capital IQ , on the heels of positive clinical data...
JNJ: 103.28 (-0.51), BIIB: 334.65 (-2.09), PFE: 31.42 (+0.26), DB: 28.36 (-0.46), LLY: 69.72 (+0.35)

Stocks Turn Lower as 'Structural Flaws' in Global Economy Surface
at The Street - Tue Jan 06, 10:10AM CST
Stocks turn lower after Monday's broad selloff.
YHOO: 49.21 (+0.08), JNJ: 103.28 (-0.51), COH: 36.30 (-0.43), WBA: 74.69 (+0.19), AOL: 46.25 (+1.51), VZ: 47.04 (+0.47)

Early Glance: Pharmaceuticals companies
AP - Tue Jan 06, 9:37AM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies are up at 10 a.m.:
JNJ: 103.28 (-0.51), BAX: 71.11 (-0.38), PFE: 31.42 (+0.26), BMY: 58.48 (-0.10)

Early Glance: Medical Devices companies
AP - Tue Jan 06, 9:37AM CST
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 10 a.m.:
ZMH: 115.80 (-0.99), JNJ: 103.28 (-0.51), MDT: 71.22 (-0.36), BAX: 71.11 (-0.38)

Watch for Shares of Johnson & Johnson (JNJ) to Approach Resistance at $105.12
Comtex SmarTrend(R) - Tue Jan 06, 9:31AM CST
Johnson & Johnson (NYSE:JNJ) has opened bullishly above the pivot of $104.07 today and has reached the first level of resistance at $104.45. Should the shares continue to rise, the resistance pivots of $105.12 and $106.16 will be of interest.
JNJ: 103.28 (-0.51)

Company News for January 06, 2015 - Corporate Summary
Zacks Equity Research - Zacks Investment Research - Tue Jan 06, 9:10AM CST
Companies in the News are: KITE,AMGN,STI,ISIS,NPSP,GS
JNJ: 103.28 (-0.51), GS: 184.53 (-3.81), ISIS: 65.44 (-2.73), KITE: 71.45 (+1.70), NPSP: 41.05 (+2.92), STI: 39.08 (-1.16), AMGN: 152.90 (-5.09)

Johnson & Johnson Dividend Stock Analysis
Roadmap2Retire - at Seeking Alpha - Tue Jan 06, 8:19AM CST

JNJ: 103.28 (-0.51)

My Income Portfolio Quarterly Update (Q4 2014)
Invest Yourself - at Seeking Alpha - Tue Jan 06, 8:13AM CST

AMLP: 16.95 (-0.23), GE: 24.07 (-0.53), MAIN: 28.34 (-0.80), HSY: 103.32 (+0.34), WMT: 86.31 (+0.66), AWK: 53.25 (+0.14), O: 50.27 (+0.65), INTC: 35.28 (-0.67), PEP: 93.02 (-0.71), JNJ: 103.28 (-0.51), DE: 85.73 (-0.72), WY: 36.07 (-0.04), DD: 70.89 (-0.83), LTC: 45.00 (+0.44), CSCO: 27.05 (-0.01), NSC: 103.00 (-3.39), HYD: 31.10 (+0.07), WFC: 52.09 (-1.11), PGX: 14.73 (+0.01), SO: 49.75 (+0.59), WM: 51.27 (+0.04), DRI: 58.19 (+0.20), ADM: 49.23 (-0.99), CVX: 108.03 (-0.05), AFL: 58.95 (-0.53)

Stock Futures Slip Into Red as Crude Oil Rout Continues
at The Street - Tue Jan 06, 7:58AM CST
Stock futures turn lower on Tuesday, triggered by a selloff of crude oil.
YHOO: 49.21 (+0.08), JNJ: 103.28 (-0.51), AOL: 46.25 (+1.51), AAL: 53.04 (-0.84), JBLU: 14.97 (-0.25), VZ: 47.04 (+0.47), LUV: 40.46 (-1.18)

Johnson & Johnson Announces Start of Phase 1 Clinical Trial of Ebola Vaccine Regimen
PR Newswire Europe - Tue Jan 06, 6:51AM CST
- Company Has Produced More Than 400,000 Vaccine Regimens for Use in Large-Scale Clinical Trials by April 2015
JNJ: 103.28 (-0.51)

J&J begins Ebola vaccine trial in U.K.
Seeking Alpha - at Seeking Alpha - Tue Jan 06, 3:07AM CST

JNJ: 103.28 (-0.51)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

DFRobot & Sensirion Unveil Cutting-Edge Formaldehyde Sensor

Game-Changing Sensor Technology Hits the Market It's not every day that two heavyweights team up and deliver something that might just shake up an entire sector. That's exactly what's happening with DFRobot and Sensirion's latest joint venture. Launching the SFA40 Formaldehyde Module, these companies are getting down and dirty with air quality detection like never before....

Big Sipz Rides RTD Wave With Vodka-Based Lyte Ade

Cracking Into a New Segment Well, it looks like Big Sipz is shaking things up with their latest concoction—Lyte Ade. In the beverage world, where spiked seltzers and canned cocktails have run riot, Big Sipz is kicking open the door to the ready-to-drink (RTD) segment with a vodka twist. This isn't just any can; we're talking about a fancy 500ml resealable Tetra Pak...

IOS Chicks to Shine on 'All Access' with Andy Garcia

How Industrial Outdoor Storage Shapes Our World You drive by them every day, those sprawling lots of trucks and containers—you might not even give them a second glance. But they're the backbone of commerce, the unsung heroes ensuring everything runs like clockwork. IOS Chicks, a trailblazing all-women commercial real estate team, is slated to unravel this world on 'All...

Latch Reports Q3 2026: Software Shines Amid Losses

Latch's Performance: A Crunch Between Software and Setbacks The stock ticker might say "LTCH," but lately, Latch Inc. is feeling more like "OUCH" for investors. While they're trumpeting a solid 18% boost in software revenue, the numbers tell a mixed story. Yeah, their software side is singing, but hardware and services took a nosedive, dragging total revenue down 18.9%...

Hornets Expand 5G Network Across New Performance Center

Boosting Connectivity with Boldyn Networks Well, the Charlotte Hornets are making moves, folks—beyond just the basketball court. Their play isn't a buzzer-beater this time but a calculated strategy to slap a 5G facelift onto their domain. Partnering with Boldyn Networks, they've spun a web of high-performance cellular sparks across both the Spectrum Center and their...

A New Era of Loyalty Commerce The winds are changing in the loyalty game, and it's about time someone shook things up. Squeez has teamed up with Qentelli, thanks to a $1 million investment, to kick-start this next wave of commerce. And boy, it's not just about money—it's like combining brains with brawn. Squeez isn't just offering loyalty programs anymore; they're...

Contract Signatures: The Black Hole of Business Time

Why Do Signatures Take Ages to Nail Down? This is what’s driving us all a bit closer to the edge. Imagine you've slogged through drafting, approvals, haggling over terms, and you think you're on the home stretch—only to discover that getting signatures is a bottleneck more tangled than a bowl of spaghetti. ContractSafe just served up another pile of stats with their...

Omni Helicopters Secures $38M in New Financing Deals

Omni Helicopters Charts New Financial Horizons When Omni Helicopters International (OHI) rawly gathers R$200 million under its financial belt, it’s clear someone’s eyeing horizons beyond the immediate. This hefty chunk, clocking in at roughly $38 million, emerges from a duo of noteworthy financing facilities and marks a strategic maneuver as OHI aligns itself for cash...

Poland Bolsters Defense with SATIM SAR Software

Poland's Defense Strategy Enters a New Era Scrap what you know about sitting around waiting for intelligence. Poland's Ministry of National Defence has jumped on a new gig with SATIM to revolutionize how they handle satellite radar imagery. This ain't child's play—this deal's all about putting the pedal to the metal with SAR, or synthetic aperture radar, analytics under...

Drowsy Driving Forum Spurs United Call for Safety Action

A Fresh Coalition Against a Familiar Foe On a brisk late October day, the National Sleep Foundation (NSF) pulled together a motley crew of road safety veterans, vehicle makers, crash sniffers, and sleep legends at the National Press Club. This wasn't just another talkfest. With an estimated 61% of U.S. adults reportedly driving while half-asleep, something finally shook...